All In Biotech

Drug Trial Radar · NCT07278479

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

A Phase 1/2a Study to Assess Safety, Tolerability, and Efficacy of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

138

Planned (sponsor's estimate)

Start

May 18, 2026

Primary completion

Sep 2028

Study completion Sep 2032

Sponsor

Lead sponsor
Molecular Partners AGIndustry
Sponsor type
Industry
Collaborators
Orano Med LLC
First posted
Dec 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.

Conditions

  • Large Cell Neuroendocrine Carcinoma
  • Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)
  • Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
  • Small Cell Lung Cancer (SCLC)
  • Gastroenteropancreatic NEC (GEP NEC)
  • NEC of the Bladder
  • Other DLL3 Expressing epNEC

Interventions

  • [212Pb]Pb-MP0712Drug

    Radioligand Therapy

  • [203Pb]Pb-MP0712Other

    Radioligand Imaging Agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess incidence and severity of safety events following administration of [212Pb]Pb-DOTAM-MAM279Time frame: until 5 years after last dose
  2. To assess dose modifications of [212Pb]Pb-DOTAM-MAM279Time frame: until 5 years after last dose
  3. To estimate the maximum tolerated dose (MTD) and/or to define the recommended phase 2 dose (RP2D) for SCLC/LCNEC of the lung and epNECsTime frame: Phase 1, from start of treatment to end of first cycle (day 1 - 28)
  4. To evaluate the preliminary anti-tumor activity of [212Pb]Pb-DOTAM-MAM279 in the dose expansion partTime frame: Phase 2a only; 12 months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of Miami

    Miami, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Emory University Hospital

    Atlanta, Georgia · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • United Theranostics

    Glen Burnie, Maryland · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • United Theranostics

    Princeton, New Jersey · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.